Thursday, 25 February 2021

Opto Circuits appoints Krishna Sudheendra as group CFO

04 March 2013 | News | By BioSpectrum Bureau

Opto Circuits appoints Krishna Sudheendra as group CFO

Opto Circuits a leading developer and manufacturer of medical equipment and interventional devices for the global markets, appointed Krishna Sudheendra as the Group Chief Financial Officer. This was approved by the Board of Directors in their meeting held on March 1st, 2013.

Most recently, Krishna was the CFO at UST Global, a global IT services and solutions provider. Over 9 years with UST Global, he successfully secured funding and investment to scale the company through an exciting growth phase. In addition to strengthening global operations, he implemented strong financial systems and controls to optimize performance and productivity. He implemented best in class corporate governance, risk and compliance frameworks. During this period, he also established credible relationships with investors, bankers and financial institutions. In 2011, Krishna was nominated by Orange County Business Journal, as "CFO of the Year - 2011" for his contribution to the company.

Krishna is a Certified Public Accountant from Denver, Colorado and is a member of The Institute of Chartered Accountants of India. Opto Circuits is a vertically integrated multinational medical technology Group that specializes in primary, acute and critical care products for the global markets. Group companies such as Cardiac Science, Criticare, Eurocor, Mediaid, AMDL and Unetixs Vascular are leaders in cardiac and vital signs monitors, emergency cardiac care equipment, vascular treatments and sensing technologies.

Commenting on the appointment, Vinod Ramnani, Chairman and Managing Director, Opto Circuits, said, "We gladly welcome Krishna Sudheendra as Group Chief Financial Officer of Opto Circuits. Considering his international professional experience in the key areas of financial management, he will be able to add value to the Company immediately. Additionally, his strong relationships and a track record of performance improvement will lend depth and strength to our global leadership team. As a Company, we are well positioned for the next phase of growth."


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls